Orchestra Biomed Hldgs Inc (OBIO) Stock Price, Quote & News

Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications,...

Industry: Biotechnology

Sector: Healthcare

Phone: 215 862 5797

Website: www.orchestrabiomed.com

Address:

150 Union Square Drive, New Hope, United States

BinaryLogic May. 29 at 8:43 AM

$MIST $RCKT $ABCL $OBIO $IMRX

0 · Reply

mrm321 May. 28 at 5:00 PM

$OBIO it’s truly genius. They drop the price down to 3.90 then it goes to 4.10 and then drops back down to 3.9 and rinse and repeat. They are playing you, so why not just join them? This rinse and repeat literally happens every 72 hours. You can’t lose

0 · Reply

mhaven2020 May. 22 at 2:23 PM

$OBIO 🤪

0 · Reply

dick_dasterdly May. 22 at 9:43 AM

$OBIO I am really liking it here. I really am. The catalysts are in the chamber..

0 · Reply

mhaven2020 May. 21 at 2:10 PM

$ELDN day 22 of 25 expected hold time for target of 20%. Target exit around 4.50(+/- 5%). Starting to sizzle! $OBIO day 3.

0 · Reply

ItsAllAboutBeingFirst May. 20 at 11:44 PM

$AIRS $OBIO $RNTX $TOI

0 · Reply

mhaven2020 May. 18 at 4:32 PM

$OBIO solid

0 · Reply

ItsAllAboutBeingFirst May. 18 at 1:58 PM

$KZIA $AIRS $OBIO $RNTX Were here all week

0 · Reply

mhaven2020 May. 18 at 1:48 PM

$ELDN $APPS $RXT I will probably in start entering into $OBIO and $PEW for a couple of days. Entry (PEW) @ 2.75 to 2.87 and (OBIO) 3.50 to 3.77. Expected hold time of between 14 and 20 days . Expected return 20% +. I am on day 19 of an expected hold time of 25. My current entry is averaged down to 3.75 and target exit of between 4.15 and 4.37. This would yield between a 10% and 16% profit. Good Luck and Happy Hunting!

0 · Reply

mrm321 May. 15 at 7:17 PM

$OBIO bummer of a day. People collecting profit here

0 · Reply

Orchestra BioMed price target lowered to $10 from $12 at B. Riley

May 19, 2026, 8:30 AM EDT - 10 days ago

Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference

2026-05-13T09:15:10.000Z - 16 days ago

Orchestra BioMed price target raised to $13 from $12 at Barclays

2026-05-12T21:08:53.000Z - 16 days ago

Orchestra BioMed reports Q1 EPS (33c), consensus (44c)

May 12, 2026, 4:18 PM EDT - 16 days ago

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

2026-05-12T14:08:39.000Z - 17 days ago

Orchestra BioMed gives clinical, regulatory update on BACKBEAT trial timeline

MDT

May 12, 2026, 8:30 AM EDT - 17 days ago

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

May 12, 2026, 7:00 AM EDT - 17 days ago

Orchestra BioMed Holdings Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 17 days ago

Orchestra BioMed Holdings Earnings release: Q1 2026

2026-05-07T05:00:15.000Z - 22 days ago

Orchestra BioMed receives $15M payment from Ligand

LGND

May 6, 2026, 8:01 AM EDT - 23 days ago

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

May 6, 2026, 8:00 AM EDT - 23 days ago

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

MDT

2026-04-30T19:15:18.000Z - 4 weeks ago

Orchestra granted additional breakthrough device designation for AVIM therapy

MDT

Apr 30, 2026, 9:00 AM EDT - 4 weeks ago

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

MDT

Apr 29, 2026, 8:00 AM EDT - 4 weeks ago

Orchestra BioMed Holdings Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 weeks ago

Orchestra BioMed Holdings Proxy statement: Proxy filing

Apr 23, 2026, 12:00 PM EDT - 5 weeks ago

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Apr 1, 2026, 7:00 AM EDT - 2 months ago

Orchestra BioMed Holdings Slides: Corporate presentation

2026-03-12T12:28:04.000Z - 2 months ago

Orchestra BioMed reports FY25 EPS ($1.11), consensus ($1.74)

Mar 12, 2026, 8:17 AM EDT - 2 months ago

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Mar 12, 2026, 7:00 AM EDT - 2 months ago

Orchestra BioMed Holdings Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 2 months ago

Orchestra BioMed Holdings Annual report: Q4 2025

Mar 11, 2026, 8:00 AM EDT - 2 months ago

Orchestra BioMed Holdings Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 3, 2026, 9:50 AM EST - 3 months ago

Orchestra BioMed Holdings Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-03T13:22:43.000Z - 3 months ago

Orchestra BioMed announces two presentations at THT, CRT 2026 meetings

Mar 3, 2026, 8:00 AM EST - 3 months ago

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

Feb 19, 2026, 8:00 AM EST - 3 months ago

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Feb 18, 2026, 7:00 AM EST - 3 months ago

Orchestra BioMed Holdings Slides: Corporate presentation

Feb 13, 2026, 4:05 PM EST - 3 months ago

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-01-12T14:11:12.000Z - 4 months ago

Orchestra BioMed to receive up to $21M in proceeds from Vivasure acquisition

HAE

Jan 12, 2026, 9:00 AM EST - 4 months ago

Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics

HAE

2026-01-09T12:25:37.000Z - 5 months ago

Orchestra BioMed price target raised to $12 from $11 at Barclays

2025-12-10T11:05:22.000Z - 6 months ago

Orchestra BioMed initiated with a Buy at TD Cowen

Dec 8, 2025, 7:00 AM EST - 6 months ago

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

Dec 3, 2025, 11:00 AM EST - 6 months ago

Orchestra BioMed Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 7 months ago

Orchestra BioMed Holdings Transcript: Status Update

2025-11-12T10:10:12.000Z - 7 months ago

Orchestra BioMed price target lowered to $11 from $12 at Barclays

Nov 10, 2025, 4:10 PM EST - 7 months ago

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Nov 10, 2025, 7:00 AM EST - 7 months ago

Orchestra BioMed Holdings Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 7 months ago

Orchestra BioMed Holdings Quarterly report: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

Orchestra BioMed to Host Business Update Call on November 12, 2025

MDT

2025-10-31T21:05:30.000Z - 7 months ago

Orchestra BioMed files to sell 8.03M shares of common stock for holders

Oct 31, 2025, 8:00 AM EDT - 7 months ago

Orchestra BioMed Holdings Registration statement: Registration Filing

2025-10-28T12:20:59.000Z - 7 months ago

Orchestra BioMed, Terumo enter new $30M Virtue SAB agreements

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

2025-10-27T13:05:24.000Z - 7 months ago

Orchestra BioMed announces first patient enrollments in Virtue SAB

Oct 27, 2025, 9:00 AM EDT - 7 months ago

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

2025-10-09T12:15:19.000Z - 8 months ago

Orchestra BioMed announces data summary supporting AVIM Therapy

Oct 9, 2025, 8:00 AM EDT - 8 months ago

Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

MDT

2025-09-04T21:05:22.000Z - 9 months ago

Orchestra BioMed announces new data from AVIM therapy program

MDT

Sep 4, 2025, 5:00 PM EDT - 9 months ago

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Aug 26, 2025, 7:30 AM EDT - 9 months ago

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Aug 14, 2025, 8:00 AM EDT - 10 months ago

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

Aug 12, 2025, 4:00 PM EDT - 10 months ago

Orchestra BioMed Holdings Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 10 months ago

Orchestra BioMed Holdings Quarterly report: Q2 2025

Aug 12, 2025, 8:14 AM EDT - 10 months ago

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Aug 8, 2025, 7:00 AM EDT - 10 months ago

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

Aug 1, 2025, 7:59 AM EDT - 10 months ago

Orchestra BioMed Announces Pricing of $40 Million Public Offering

Jul 31, 2025, 4:02 PM EDT - 10 months ago

Orchestra BioMed Announces Proposed Public Offering

Jul 31, 2025, 4:01 PM EDT - 10 months ago

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

LGND MDT

Jun 18, 2025, 9:30 AM EDT - 1 year ago

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

Jun 5, 2025, 3:45 PM EDT - 1 year ago

Orchestra BioMed Holdings Transcript: The Jefferies Global Healthcare Conference 2025

May 22, 2025, 11:30 AM EDT - 1 year ago

Orchestra BioMed Holdings Transcript: Sidoti May Micro-Cap Virtual Conference

May 12, 2025, 4:28 PM EDT - 1 year ago

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 11, 2025, 6:00 PM EDT - 1 year ago

Orchestra BioMed Holdings Earnings release: Q1 2025

May 11, 2025, 6:00 PM EDT - 1 year ago

Orchestra BioMed Holdings Quarterly report: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Orchestra BioMed Holdings Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Orchestra BioMed Holdings Proxy statement: Proxy Filing

Apr 29, 2025, 10:30 AM EDT - 1 year ago

Orchestra BioMed Holdings Transcript: Chardan Capital’s Trending Issues in Drug Development Conference

Apr 29, 2025, 9:00 AM EDT - 1 year ago

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Apr 23, 2025, 9:00 AM EDT - 1 year ago

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

MDT

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Mar 31, 2025, 4:21 PM EDT - 1 year ago

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Mar 30, 2025, 6:00 PM EDT - 1 year ago

Orchestra BioMed Holdings Annual report: Q4 2024

Mar 3, 2025, 2:30 PM EST - 1 year ago

Orchestra BioMed Holdings Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 8:00 AM EST - 1 year ago

Orchestra BioMed to Present at Upcoming Investor Conferences

Feb 18, 2025, 8:00 AM EST - 1 year ago

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Feb 12, 2025, 10:43 AM EST - 1 year ago

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Dec 4, 2024, 3:00 PM EST - 1 year ago

Orchestra BioMed Holdings Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:05 PM EST - 1 year ago

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 8:00 AM EST - 1 year ago

Orchestra BioMed Holdings Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 4:12 PM EST - 1 year ago

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 12, 2024, 4:00 PM EST - 1 year ago

Orchestra BioMed Holdings Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Orchestra BioMed Holdings Quarterly report: Q3 2024

Aug 12, 2024, 4:20 PM EDT - 1 year ago

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 12, 2024, 3:00 PM EDT - 1 year ago

Orchestra BioMed Holdings Quarterly report: Q2 2024

Aug 12, 2024, 3:00 PM EDT - 1 year ago

Orchestra BioMed Holdings Earnings release: Q2 2024

May 22, 2024, 8:43 AM EDT - 2 years ago

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

May 16, 2024, 7:00 AM EDT - 2 years ago

Orchestra BioMed Holdings Slides: Investor Presentation

May 15, 2024, 8:00 AM EDT - 2 years ago

Orchestra BioMed Holdings Registration statement: Registration Filing

May 13, 2024, 4:58 PM EDT - 2 years ago

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

May 13, 2024, 7:00 AM EDT - 2 years ago

Orchestra BioMed Holdings Quarterly report: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Orchestra BioMed Holdings Earnings release: Q1 2024

Apr 30, 2024, 8:30 AM EDT - 2 years ago

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Orchestra BioMed Holdings Proxy statement: Proxy Filing

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Orchestra BioMed Holdings Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Orchestra BioMed Holdings Registration statement: Registration Filing

Mar 27, 2024, 4:17 PM EDT - 2 years ago

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Orchestra BioMed Holdings Annual report: Q4 2023

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Orchestra BioMed Holdings Earnings release: Q4 2023

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Orchestra BioMed Holdings Registration statement: Registration Filing

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Mar 7, 2024, 8:00 AM EST - 2 years ago

Orchestra BioMed to Participate in Upcoming Investor Conferences

Mar 6, 2024, 8:37 AM EST - 2 years ago

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Jan 8, 2024, 7:30 AM EST - 2 years ago

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Nov 13, 2023, 4:21 PM EST - 2 years ago

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

BinaryLogic May. 29 at 8:43 AM

$MIST $RCKT $ABCL $OBIO $IMRX

0 · Reply

mrm321 May. 28 at 5:00 PM

0 · Reply

mhaven2020 May. 22 at 2:23 PM

$OBIO 🤪

0 · Reply

dick_dasterdly May. 22 at 9:43 AM

$OBIO I am really liking it here. I really am. The catalysts are in the chamber..

0 · Reply

mhaven2020 May. 21 at 2:10 PM

$ELDN day 22 of 25 expected hold time for target of 20%. Target exit around 4.50(+/- 5%). Starting to sizzle! $OBIO day 3.

0 · Reply

ItsAllAboutBeingFirst May. 20 at 11:44 PM

$AIRS $OBIO $RNTX $TOI

0 · Reply

mhaven2020 May. 18 at 4:32 PM

$OBIO solid

0 · Reply

ItsAllAboutBeingFirst May. 18 at 1:58 PM

$KZIA $AIRS $OBIO $RNTX Were here all week

0 · Reply

mhaven2020 May. 18 at 1:48 PM

0 · Reply

mrm321 May. 15 at 7:17 PM

$OBIO bummer of a day. People collecting profit here

0 · Reply

Jordan3333 May. 13 at 12:27 PM

$OBIO it looks like there might be approval before the end of 2027, and sales already at the beginning of 2028, what price will $OBIO be at if sales for 2028 are already $100MM and going north

0 · Reply

dick_dasterdly May. 13 at 3:43 AM

$OBIO This is ridiculous, right ? Listen.. I was hooked at " royalties". Are you effing kidding?🤔 I've ran out of bags for now. So now I am using anything I can to hoard more shares.

0 · Reply

mrm321 May. 13 at 2:38 AM

$OBIO Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial presentation at major cardiology conference in Q2 2027 and subsequent marketing. Slow and steady wins the race. See yall at $5

0 · Reply

focafoca99 May. 12 at 8:24 PM

$OBIO released Q1 2026 results, noting a $35M capital boost, FDA breakthrough designations for AVIM Therapy and progress on the BACKBEAT

0 · Reply

TheBearVsTheBull May. 12 at 2:39 PM

$OBIO Completion of enrollment Q3 2026 End point data Q2 2027 Medtronic submitted FDA Approval immediately after Q2 2027 I understand that this timeline is a little bit later than I anticipated. But there should be no reason this stock is down. Accumulating more shares down here!!

0 · Reply

dick_dasterdly May. 12 at 3:48 AM

$OBIO Accumulating. Enough said.

0 · Reply

BinaryLogic May. 10 at 12:51 AM

$OBIO Ligand and $MDT just injected another $35M into the Company to support ongoing cardiac-related studies (AVIM and Virtue SAB) for hypertension and atherosclerosis, respectively. Success on either/both of these studies should drive the SP materially higher, a multiple of current valuation. The stock continues to consolidate at/around $4.0 in the interim, as these FDA breakthrough studies undergo their final, pivotal trials concurrently. https://www.stocktitan.net/news/OBIO/orchestra-bio-med-receives-15-million-investment-from-ligand-under-elm5rjhajhg7.html

1 · Reply

BinaryLogic May. 9 at 11:02 AM

$MIST $RCKT $ABCL $OBIO $IMRX [Again] Investors are heavy in semi-conductors, AI/HPC and O&G related stocks presently which has created opportunities in-particular in biotechnology, small and large cap alike (IMO). That is not to suggest that major reversals here are imminent, but the setups are becoming increasingly opportunistic (IMO) intermediate term. UNCY COCH JSPR SCNX RANI TRAW NVAX MDT BSX

0 · Reply

dick_dasterdly May. 8 at 3:24 PM

$OBIO Okay. After 3 months on the top of my watchlist , I AM IN on this gem. I see the potential here..

0 · Reply

ItsAllAboutBeingFirst May. 8 at 1:34 AM

$TOI great earnings mgt - keep walking her up $AIRS - your up next $RNTX - loving the action - no brainer buy $OBIO - steady eddie - buy dips

0 · Reply

ItsAllAboutBeingFirst May. 6 at 2:54 PM

$AIRS $KZIA $OBIO $RNTX Rntx - deal closed monday - starting to wake up - major catalyst less than 6'm Smart money & clean (derisked and no overhang w a clean cap table at 1$ - ill join em - no brainer Airs - wont be denied - space is heating up - shorts got this wrong Obio - great news today - i buy Kzia - up 100 percent and still holding

0 · Reply

Stock_Catcher May. 6 at 12:04 PM

$OBIO Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

0 · Reply

Market Cap	236.53M
Revenue (ttm)	33.48M
Net Income (ttm)	-52.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-157.41%
Debt to Equity Ratio	0.35

Volume	124,000
Avg Vol	214,126
Day's Range	N/A - N/A
Shares Out	59.88M
Stochastic %K	62%
Beta	0.52
Analysts	Strong Sell
Price Target	$12.29